Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea Patients
Pilot, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study, to Evaluate the Tolerability and Safety of FXFM244 Antibiotic Foam and to Monitor Its Clinical Effect in Moderate to Severe Rosacea Patients
Sponsor: Vyne Therapeutics Inc.
Terminated
Difficulty in recruitment
Other terminated trials from Vyne Therapeutics Inc.
- Non-segmental Vitiligo · Sep 2025
- Atopic Dermatitis · Phase PHASE3 · Jun 2020
- Burns · Phase PHASE2 · Jan 2017
- Alcohol Dependence · Phase PHASE2 · Mar 2010
More terminations from Vyne Therapeutics Inc.
Other Rosacea trials with similar outcome
A PHASE2 clinical study on Rosacea, this trial is terminated or withdrawn. The trial is conducted by Vyne Therapeutics Inc. and has accumulated 7 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vyne Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .